Australië - Engels - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - oseltamivir phosphate, quantity: 59.1 mg (equivalent: oseltamivir, qty 45 mg) - capsule, hard - excipient ingredients: povidone; croscarmellose sodium; purified talc; sodium stearylfumarate; pregelatinised maize starch; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; iron oxide black; indigo carmine; butan-1-ol; ethanol; shellac; methanol - tamiflu is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,tamiflu is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - oseltamivir phosphate, quantity: 39.4 mg (equivalent: oseltamivir, qty 30 mg) - capsule, hard - excipient ingredients: povidone; croscarmellose sodium; purified talc; sodium stearylfumarate; pregelatinised maize starch; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; iron oxide black; indigo carmine; butan-1-ol; ethanol; shellac; methanol - tamiflu is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,tamiflu is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - oseltamivir phosphate, quantity: 98.5 mg (equivalent: oseltamivir, qty 75 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; purified talc; povidone; croscarmellose sodium; sodium stearylfumarate; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; iron oxide black; indigo carmine; butan-1-ol; ethanol; shellac; methanol - tamiflu is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,tamiflu is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - saquinavir mesilate, quantity: 571.5 mg (equivalent: saquinavir, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; triacetin; croscarmellose sodium; titanium dioxide; hypromellose; purified talc; iron oxide red; lactose monohydrate; iron oxide yellow; magnesium stearate - invirase (saquinavir) is indicated for the treatment of hiv/aids in adults and children 12 years of age or older. clinical studies indicate that saquinavir should only be used in combination with ritonavir and other anti-retroviral therapies (see clinical trials). this indication is based on changes in surrogate markers. at present there are no results from controlled clinical trials evaluating the effect of regimens containing saquinavir on hiv disease progression or survival (see clinical trials).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; purified talc; povidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; hyprolose; iron oxide red; macrogol 400 - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule, hard - excipient ingredients: povidone; titanium dioxide; iron oxide yellow; iron oxide red; croscarmellose sodium; gelatin; pregelatinised maize starch; indigo carmine; magnesium stearate - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - faricimab, quantity: 120 mg/ml - injection, solution - excipient ingredients: histidine; acetic acid; methionine; sodium chloride; sucrose; polysorbate 20; water for injections - vabysmo is indicated for the treatment of:,- neovascular (wet) age-related macular degeneration (namd),- diabetic macular oedema (dmo).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - pralsetinib, quantity: 100 mg - capsule, hard - excipient ingredients: sodium bicarbonate; microcrystalline cellulose; magnesium stearate; citric acid; pregelatinised starch; hypromellose; titanium dioxide; brilliant blue fcf; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - non-small cell lung cancer (nsclc),gavreto has provisional approval in australia for the treatment of adult patients with locally advanced or metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc). the decision to approve this indication has been made on the basis of overall response rate (orr) and duration of response (dor) in single-arm trials. continued approval of this indication depends on verification and description of benefit in confirmatory trials. ret-fusion positive thyroid cancer,gavreto has provisional approval in australia for the treatment of adult patients with advanced or metastatic ret-fusion positive thyroid cancer that is refractory to (or unsuitable for) radioactive iodine and who have progressed on or are unable to tolerate lenvatinib or sorafenib. the decision to approve this indication has been made on the basis of overall response rate (orr) and duration of response (dor). continued approval of this indication depends on verification and description of benefit in confirmatory trials.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - vismodegib, quantity: 150 mg - capsule, hard - excipient ingredients: purified talc; iron oxide red; gelatin; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; iron oxide black; shellac; lactose monohydrate; povidone; magnesium stearate; sodium lauryl sulfate - erivedge is indicated for the treatment of adult patients with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - baloxavir marboxil, quantity: 40 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; povidone; sodium stearylfumarate; purified talc; hypromellose; titanium dioxide - treatment of influenza,xofluza is indicated for the treatment of uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:,? otherwise healthy, or,? at high risk of developing influenza complications.,prophylaxis of influenza,xofluza is indicated for the post-exposure prophylaxis of influenza in patients aged 12 years of age and older following contact with an individual who has confirmed influenza.,vaccination is the preferred method of routine prophylaxis against infection with influenza virus.